Within the last years, targeted therapies using tyrosine kinase inhibitors (TKI) have resulted in a rise in progression-free survival and response price for any subgroup of non-small cell lung cancer (NSCLC) individuals harbouring specific gene abnormalities weighed against chemotherapy. with an increase of level of sensitivity SU11274 to EGFR-TKIs treatment [6]. Regrettably, almost all individuals… Continue reading Within the last years, targeted therapies using tyrosine kinase inhibitors (TKI)